We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$35.3M
Cap. Flow
+$33.3M
Cap. Flow %
18.49%
Top 10 Hldgs %
21.58%
Holding
287
New
78
Increased
46
Reduced
73
Closed
55

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.54M
2
CHRS icon
Coherus Oncology
CHRS
+$3.29M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.71M
4
EMBC icon
Embecta
EMBC
+$2.55M
5
RPV icon
Invesco S&P 500 Pure Value ETF
RPV
+$2.33M

Top Sells

Rank Stock Value
1
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$4.1M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$2.81M
3
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$2.81M
4
INVA icon
Innoviva
INVA
+$2.07M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$1.63M

Sector Composition

Rank Sector Weight
1 Healthcare 59.9%
2 Real Estate 10.66%
3 Financials 4.01%
4 Technology 3.46%
5 Consumer Discretionary 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEN icon
76
Lennar Class A
LEN
$20.2B
$742K 0.41%
6,121
+1,093
+22% +$119K
NOTE
77
DELISTED
FiscalNote
NOTE
$728K 0.4%
+16,667
New +$468K
NNDM
78
Nano Dimension
NNDM
$326M
$723K 0.4%
250,000
– –
AMRN
79
Amarin Corp
AMRN
$292M
$696K 0.39%
29,250
+4,250
+17% +$109K
GILD icon
80
Gilead Sciences
GILD
$167B
$655K 0.36%
8,500
– –
MITT
81
TPG Mortgage Investment Trust
MITT
$243M
$642K 0.36%
+104,821
New +$596K
DPRO
82
Draganfly
DPRO
$155M
$640K 0.36%
20,000
– –
PNT
83
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$634K 0.35%
+70,000
New +$617K
EXEL icon
84
Exelixis
EXEL
$14.1B
$631K 0.35%
33,000
– –
NUVB icon
85
Nuvation Bio
NUVB
$2.02B
$621K 0.34%
345,000
– –
BBJP icon
86
JPMorgan BetaBuilders Japan ETF
BBJP
$17.1B
$587K 0.33%
11,389
-2,523
-18% -$126K
VTRS icon
87
Viatris
VTRS
$20.1B
$549K 0.3%
+55,000
New +$525K
QURE icon
88
uniQure
QURE
$2.77B
$544K 0.3%
+47,500
New +$900K
ELS icon
89
Equity Lifestyle Properties
ELS
$12.8B
$543K 0.3%
+8,111
New +$540K
EWA icon
90
iShares MSCI Australia ETF
EWA
$1.43B
$520K 0.29%
+23,064
New +$528K
CLDX icon
91
Celldex Therapeutics
CLDX
$2.77B
$509K 0.28%
15,000
– –
HYD icon
92
VanEck High Yield Muni ETF
HYD
$4.49B
$497K 0.28%
9,680
+4,840
+100% +$248K
CAH icon
93
Cardinal Health
CAH
$53.5B
$493K 0.27%
+5,217
New +$441K
AUPH icon
94
Aurinia Pharmaceuticals
AUPH
$2.05B
$484K 0.27%
50,000
-27,500
-35% -$285K
CI icon
95
Cigna
CI
$74.5B
$458K 0.25%
1,631
+380
+30% +$99K
CWB icon
96
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.78B
$421K 0.23%
+6,014
New +$404K
EMHY icon
97
iShares JPMorgan EM High Yield Bond ETF
EMHY
$613M
$417K 0.23%
11,864
-1,314
-10% -$45.4K
MCK icon
98
McKesson
MCK
$98.5B
$412K 0.23%
965
+234
+32% +$89.9K
EMB icon
99
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.6B
$412K 0.23%
4,756
+3,465
+268% +$296K
PBP icon
100
Invesco S&P 500 BuyWrite ETF
PBP
$348M
$410K 0.23%
18,538
+4,885
+36% +$105K
2 3
4
5 6

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, AlphaCentric Advisors held 287 positions worth $180M, up 24% from $145M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

AlphaCentric Advisors deployed $33.3M of net new capital in Q2 2023, opening 78 new positions and adding to 46 existing holdings. Its largest new stake was Embecta: 93,500 shares worth $2.02M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $4.1M trimmed.

  • AlphaCentric Advisors's largest Q2 2023 buy was Embecta: 93,500 shares worth $2.02M.
  • AlphaCentric Advisors added most to Jazz Pharmaceuticals in Q2 2023, an estimated $4.54M increase.
  • AlphaCentric Advisors's biggest Q2 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $4.1M.
  • AlphaCentric Advisors fully exited Invesco QQQ Trust in Q2 2023, selling an estimated $2.81M.
  • AlphaCentric Advisors's ten largest holdings make up 22% of its $180M portfolio in Q2 2023.
  • AlphaCentric Advisors opened 78 new positions and closed 55 in Q2 2023.
  • AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $180M.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.